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Abstract
In the past few years, case-control studies of common diseases have shifted their focus from single genes to whole exomes.
New sequencing technologies now routinely detect hundreds of thousands of sequence variants in a single study, many of
which are rare or even novel. The limitation of classical single-marker association analysis for rare variants has been a
challenge in such studies. A new generation of statistical methods for case-control association studies has been developed
to meet this challenge. A common approach to association analysis of rare variants is the burden-style collapsing methods
to combine rare variant data within individuals across or within genes. Here, we propose a new hybrid likelihood model that
combines a burden test with a test of the position distribution of variants. In extensive simulations and on empirical data
from the Dallas Heart Study, the new model demonstrates consistently good power, in particular when applied to a gene
set (e.g., multiple candidate genes with shared biological function or pathway), when rare variants cluster in key functional
regions of a gene, and when protective variants are present. When applied to data from an ongoing sequencing study of
bipolar disorder (191 cases, 107 controls), the model identifies seven gene sets with nominal p-valuesv0.05, of which one
MAPK signaling pathway (KEGG) reaches trend-level significance after correcting for multiple testing.
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Introduction
Research efforts over the past few years have yielded an
explosion of exome sequencing studies and exomic variation data
(reviewed in [1,2]). One surprising result has been the discovery of
hundreds of thousands of novel and rare nonsilent variants in
protein coding genes, some of which may have functional
consequences related to human health. Common diseases, once
hypothesized to be primarily due to common variants [3], are now
believed to have heterogeneous genetic causes, due to both
common and rare variants [4–6].
These developments have created demand for a new generation
of statistical and informatics approaches. Increasingly powerful
analysis methods have been developed to enable detection of
association between phenotype and variants with small to
moderate effect sizes (reviewed in [6]). Rather than testing each
variant individually, variants can be collapsed or summed with a
‘‘burden’’ approach, in which the strength of phenotypic
association is considered with respect to a group of variants
occurring at a common region or allelic frequency threshold [7–
10]. The contribution of each variant to the association may be
weighted by frequency or bioinformatically predicted impact [10].
Burden strategies yield a power gain, compared to independent
tests of single variants, but they lose power when variants with a
neutral or protective effect are included. Regression models [11]
and overdispersion tests [12] have been designed to detect variants
that affect phenotype, regardless of the direction of the effect
(deleterious or protective). New approaches continue to be
introduced, such as a mixture model that incorporates gene-gene
interactions and an adaptive weighting procedure [13]. A recent
study has even suggested that single-variant test statistics may be
more powerful than collapsing strategies on real data [14].
Importantly, no single method appears to be superior for all
phenotypes, genomic regions, disease models, and populations
[6,15,16].
Here we describe a new hybrid likelihood test BOMP (Burden
Or Mutation Position test), designed for case-control exome
sequencing studies, to detect the presence of causal variants in a
functional group. The functional group can be defined as a gene,
genomic region, or gene set (multiple genes involved in a pathway
or biological process). The test can incorporate variant weighting
by bioinformatically-predicted functional impact. We combine,
into a single statistic, a directional burden test in which low
frequency variants have increased weight and a non-directional
position distribution test that does not consider allele frequency.
Our burden test uses a collapsing strategy and metrics of variant
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functional importance, which are similar to previously published
burden tests (Table S1). An advantage of our test is that its
formulation into a likelihood ratio uniquely allows us to combine it
with the position distribution test. The two tests complement each
other and together yield increased power to detect biologically
important variants, particularly when applied to a gene set
containing genes with different kinds of variants (e.g., rare, low
frequency, common, protective).
To assess the utility of BOMP, we compare its power to three
leading methods for variant case-control association testing: VT
[10] a mutation burden statistic, SKAT [12] a regression model and
overdispersion test, and KBAC [13], which uses mixture modeling
and kernel density estimation. We generate simulated case-control
studies ranging from 200 to 5,000 individuals, using two
demographic growth models, and eight disease etiologies (models of
disease causation). We also apply BOMP to dichotomized empirical
data from a study of quantitative traits, the Dallas Heart Study,
which investigated the association between variants in angiopoietin-
like (ANGPTL) proteins and triglyceride metabolism [17].
In these experiments, BOMP is consistently powerful across a
spectrum of disease causality models, in simulations of case-control
studies drawn from populations of African-American and European-
American individuals, and for the ANGPTL variants from the Dallas
Heart Study. It appears to be particularly useful for detecting genes
containing causal variants when protective variants are present, when a
disease phenotype is associated with variants that cluster in key regions
on a gene, when a causal variant is common, or when applied to a
candidate gene set, rather than a single candidate gene.
Finally, we apply BOMP to identify causal gene sets in an an
ongoing, whole-exome case-control sequencing study of bipolar
disorder. We find that seven gene sets are nominally associated
with bipolar disorder and that one ‘‘MAPK signaling pathway’’
(KEGG) trends towards significance after correcting for multiple
gene sets tested. Notably, this pathway has been implicated
previously in bipolar disorder [18].
Results
We evaluated the power of the BOMP hybrid likelihood model
with both simulations and empirical data from the Dallas Heart
Study [17]. All results were compared to several leading statistical
methods to detect causal variation in case-control association
studies. We attempted to select representative methods for burden,
regression, and mixture modeling approaches.
First, we assessed the power of BOMP to detect genes with
causal variants in an extreme phenotype case-control study, for a
disease with 1% population prevalence, and significance level
a~0:05. We considered that deleterious causal variants might
either be rare, low frequency or common and that modifying
protective variants might be present. Power to detect causal
variants was assessed initially with respect to a single candidate
gene and then for candidate gene sets, ranging in size from 2 to 24
genes. We studied gene sets in which all genes contained causal
variants and those in which only a fraction of genes contained
causal variants. Both African-American and European-American
demographic models were considered. For each combination of
attributes (disease etiology, population demographic, case-control
study size), 250 case-control studies were simulated to assess
power.
Power analysis of simulated case-control studies
In single-gene case-control study simulations, a study size of
2000 (1000 cases, 1000 controls) was required for any of the
methods to achieve at least 80% power to detect causal variants.
BOMP hadw80% power for three of the tested disease etiologies
(Common variant, KeyRegion+Protect, and Common+Protect).
When the study size was increased to 5000 (or 10000 (Figure S1)),
several of the methods (BOMP, SKAT, VT, and KBAC5P
(MAFv5%)) had w80% power for selected etiologies (Figure 1).
BOMP was consistently more powerful than other methods and
appeared to be particularly useful for certain disease etiologies
(Key region variant, Common variant, and all etiologies involving
protective variants (Table 1)). All methods were less powerful when
applied to case-control studies using the European-American
demographic model (in which variants are either rare or
singletons) (Figure S2).
Next, we explored how the power of the tested methods could
be improved by application to a candidate gene set rather than a
single candidate gene. We simulated case-control studies, in which
each genomic individual had multiple genes, all or some of which
contained causal variants. The gene sets in which all genes
contained causal variants ranged from 2 to 5 genes. Gene sets with
mixtures of casual and non-causal genes ranged from 4 to 15 genes
(ratios of causal to non-causal 3:1, 3:3, 3:6, 3:9, and 3:12). Causal
variants were equally likely to be from any of the disease etiologies
dominated by rare variants. The assumption that even 25% of
genes in a set contain causal variants is certainly optimistic, but this
experiment allowed us to compare the extent to which each
method was affected by the fraction of causal genes in a set.
When all genes in a gene set contained causal variants, power
increased for all methods as gene set size increased. When the gene
sets contained a mixture of genes, both with and without causal
variants, the power decreased with the causal to non-causal ratio.
For the African-American demographic model, BOMP and
SKAT were the most robust to gene sets with low causal to
non-causal ratio. As in the single gene experiment, all methods had
less power in the European-American demographic than in the
African-American. For the European-American, none of the
methods had power w80% for any of the gene sets. For the
African-American demographic, BOMP, SKAT, and VT had
powerw80% when gene sets of sizes 4 and 5 contained all causal
variants. BOMP was the only method with power w80% for any
of the mixed gene sets tested (gene set sizes 3,6, and 9, with ratio of
causal to non-causal 3:0, 3:3 and 3:6) (Figure 2).
Author Summary
Inexpensive, high-throughput sequencing has transformed
the field of case-control association studies. For the first
time, it may be possible to identify the genetic underpin-
nings of complex diseases, by sequencing the DNA of
hundreds (even thousands) of cases and controls and
comparing patterns of DNA sequence variation. However,
complex diseases are likely to be caused by many variants,
some of which are very rare. Taken one at a time, the
association between variant and disease phenotype may
not be detectable by current statistical methods. One
strategy is to identify regions where important variants
occur by ‘‘collapsing’’ variants into groups. Here, we
present a new collapsing approach, capable of detecting
subtle genetic differences between cases and controls. We
show, in extensive simulations and using a benchmark set
of genes involved in human triglyceride levels, that the
approach is potentially more powerful than existing
methods. We apply the new method to an ongoing
sequencing study of bipolar cases and controls and
identify a set of genes found in neuronal synapses, which
may be implicated in bipolar disorder.
Hybrid Likelihood Model for Disease Association
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Next, we reconsidered the assumption that casual variants in a
gene set were equally likely to come from a few disease etiologies.
Instead, we sampled disease etiologies from nine multinomial
distributions (Figure S3). For these experiments, the number of
candidate genes was fixed at nine and the ratio of causal to non-
causal genes was 3:6. BOMP’s power advantage over the other
tested methods was larger in this experiment than in the single
candidate gene experiment. For case-control study size of 1000,
BOMP power was w80% for the multinomial distributions
dominated by the key region variant etiology (African-American)
and etiologies involving protective variants. For case-control
study size of 2000, BOMP power was w80% for all six
multinomial distributions possible for the African-American
model (Figure 3), and SKAT power was w80% for the
multinomial distributions dominated by the key region variant
etiology (African-American) and etiologies involving protective
variants.
We explored the power of BOMP with respect to case-control
study size, using a set of 24 candidate genes as the functional
group. We varied the ratio of casual to non-causal genes from 1:3,
1:1, and 3:1. Here, causal variants were again equally likely to be
from any of the disease etiologies dominated by rare variants. For
a case-control study size of 1000, BOMP’s power exceeded 0.8,
regardless of the causal-to-non-causal gene ratio (African-Amer-
ican only), and for the 1:1 and 3:1 causal-to-non-causal gene ratios
for European-American. A study size of 200 was sufficient for
power w0:8 for 1:1 and 3:1 ratios (African-American only)
(Figure 4).
We reasoned from these results that, for a population whose
allele frequency spectrum is similar to our European-American
demographic model simulations, current whole-exome case-
control studies are not sufficiently powered. These studies lack
power to find causal variants both at the single gene level (as
proposed by [19]) and for modestly-sized gene sets. However, if
Figure 1. Single gene methods power comparison. Power estimates for BOMP, VT, SKAT, KBAC (KBAC1P=minor allele frequency defined as
v1%, KBAC5P=minor allele frequency defined as v5%). Each vertical line represents power estimates for each method, based on 250 simulated
case-control studies. AA= the case-control studies were drawn from gene populations generated with an African-American simple bottleneck
demographic model. EA= the case-control studies were drawn from gene populations generated with a European-American exponential growth
demographic model. The eight variant causality (disease etiology) models are defined in Table 1. Since the European-American demographic model
does not account for common or protective variants, etiologies involving common or protective variants were only considered for the African-
American demographic model.
doi:10.1371/journal.pgen.1003224.g001
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the allele frequency spectrum is more similar to the African-
American demographic model, BOMP may be able to detect
causal variation in larger gene sets, given the size of current whole-
exome studies.
To test this hypothesis, we considered a case-control study of
200 individuals, using a set of 100 candidate genes as the
functional group. The disease etiologies of causal genes were
sampled from three categories with the ratio of 10 (Rare variant or
Low frequency variant or Key region variant) :1 (Common
variant) : 1 (any etiology involving protective variants). Etiologies
were sampled with equal probability within each category. As
before, we varied the ratio of causal to non-causal genes in the set
from 1:3, 1:1, 3:1. BOMP power wasw0:8 for all scenarios (0.852
for 1:3, 0.956 for 1:1 and 0.956 for 3:1).
Relative contributions of mutation burden and mutation
position distribution in simulated case-control studies
We computed average power for single candidate gene case-
control studies and multiple candidate gene case-control studies
(nine genes, 3:6 causal to non-causal ratio), with respect to both
demographic models, all disease etiologies (Table 1) for single
genes, and all combinations of disease etiologies for gene sets
(Figure S3). BOMP’s hybrid likelihood model had better power
than either of its components: the mutation burden and mutation
position distribution statistics (Figure 5). The burden statistic had
more power in single-gene studies, while the position statistic had
more power in the gene set studies.
In general, mutation burden tests outperform the position
distribution statistic when causal variants are rare and are not
clustered. The position distribution test outperforms burden tests
when the number of rare variants is similar in cases and controls, but
where cases and controls differ with respect to the position
distribution of the variants. To illustrate this point, we show a case
in which burden tests would miss such a difference (Figure 6). In the
genomic region shown, cases and controls each have 9 total
variants, but an informative window segmentation yields distinct
regions in which the number of variants seen in cases and controls is
substantially different. The difference between cases and controls is
also missed by SKAT, which consider variants one at a time,
because at each position the number of variants in cases and
controls is similar. (A more detailed example is shown in Figure 7.)
Both collapsing burden and position distribution tests outper-
form SKAT when causal variants are very rare. Figure S4 shows
the power of VT, SKAT, BOMP burden, and BOMP position
Figure 2. Power estimates for multiple gene case-control studies with causal variants equally likely to be from any disease etiology
dominated by rare variants. A,B. X-axis shows number of candidate genes in 250 simulated case-control studies (approximately one-third each
from disease etiologies Rare, LowFreq and KeyRegion). All genes contain causal variants. For each method, average power is shown. Power increases
for all methods as the number of candidate genes with causal variants increases. C,D. X-axis shows the number of candidate genes and the ratio of
genes containing causal variants to those that do not contain causal variants. As the ratio decreases, the power of the tested methods also decreases.
(Tested methods are BOMP, VT, SKAT and KBAC1P=minor allele frequency defined as v1%, KBAC5P=minor allele frequency defined as v5%).
AA= the case-control studies were drawn from gene populations generated with an African-American simple bottleneck demographic model.
EA= the case-control studies were drawn from gene populations generated with a European-American exponential growth demographic model.)
doi:10.1371/journal.pgen.1003224.g002
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distribution in 10,000 simulated European-American individuals,
using our Rare and Key Region Variant disease etiologies. The
European-American populations contain a large fraction of rare
variants (Figure S2 shows exact allele frequencies and raw counts).
Our simulations of the Rare Variant etiology in this population
generate rare variants that are not clustered, and the methods with
highest power are VT burden and BOMP burden tests. In Key
Region Variant simulations where rare variants are positioned
differently in cases and controls, the position distribution statistic
has higher power than either of these burden tests.
Type 1 error
Because we used permutation to compute p-values, type I error
should be well controlled.
Dallas Heart Study
We applied the BOMP hybrid likelihood model to the analysis
of data from the Dallas Heart Study (DHS) [17]. Romeo et al.
explored genetic contributions to plasma triglyceride (TG) levels in
*3500 individuals in the DHS, by resequencing the coding
regions of several genes, including angiopoietin-like (ANGPTL)
family genes. The ANGPTL genes regulate the activity of a key
enzyme in TG metabolism, lipoprotein lipase (LPL), via post-
transcriptional modifications and were jointly associated with low
triglyceride levels by [17]. Specifically, ANGPTL3, ANGPTL4, and
ANGPTL5 were functionally validated as causal genes, playing
non-redundant roles and underlying TG levels as a functional
group [17]. The ANGPTL gene set has been analyzed in several
computational papers and used as a benchmark to compare
methods that predict the impact of rare and common variants
from sequencing data [10,12,13,20–23].
We stratified the DHS samples by ethnicity (Hispanic, non-
Hispanic white, non-Hispanic black) and gender. Because
BOMP was designed for dichotomous phenotypes, we selected
the lower and upper quartiles from each group, by TG level
(totaling 1775 individuals, with 897 cases and 878 controls).
Figure 3. Power estimates for multiple genes case-control studies with causal variants from disease etiologies randomly sampled
from nine multinomial distributions (Figure S3). Power estimates for BOMP, VT, SKAT, KBAC (KBAC1P=minor allele frequency defined asv1%,
KBAC5P=minor allele frequency defined as v5%). Each vertical line represents power estimates for each method, based on 250 simulated case-
control studies. The genomic individuals each had nine genes, of which three contained causal variants and six did not. The disease etiologies for the
three genes with causal variants were randomly sampled from nine multinomial distributions (Figure S3). AA=African-American simple bottleneck
demographic model. EA= European-American exponential growth demographic model.
doi:10.1371/journal.pgen.1003224.g003
Hybrid Likelihood Model for Disease Association
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Sixty mutations in ANGPTL3, ANGPTL4, and ANGPTL5
occurred in these individuals.
We computed a P-value for each of the three ANGPTL
genes and for the ANGPTL gene set, using BOMP (with and
without bioinformatics scores), the burden statistic VT (with
and without bioinformatics variant weighting), the overdisper-
sion statistic SKAT, and the mixture-model KBAC statistic
(with four parameter settings) (Table 2).
The hybrid BOMP test, with bioinformatics scores and allele
frequency variant weighting, had the most significant P-value for
Figure 4. BOMP Power estimates for multiple genes (24) case-control studies. Power estimates for BOMP; each estimate is based on 250
simulated case-control studies ((approximately one-third each from disease etiologies Rare, LowFreq and KeyRegion). The genomic individuals each
had 24 genes, the ratio of genes with causal variants to those without causal variants was either 1:3 (6 causal, 18 non-causal), 1:1 (12 causal, 12 non-
causal), or 3:1 (18 causal, 6 non-causal). AA=African-American simple bottleneck demographic model. EA= European-American exponential growth
demographic model.
doi:10.1371/journal.pgen.1003224.g004
Figure 5. BOMP burden and position statistics complement each other. Breakdown of contribution of BOMP mutation burden (BOMP_B)
and BOMP position distribution (BOMP_P) statistics averaged over single candidate gene power estimates (Figure 1) and multiple candidate gene
power estimates (nine genes, 3 with causal variants and 6 with no causal variants) (Figure 3) for case-control study sizes of 200, 1000, 2000, and 5000.
Combining the two statistics consistently yielded improved power with respect to each statistic on its own. The BOMP burden statistic had more
power than BOMP position for the simulations based on a single candidate gene, and vice versa in the simulations with nine candidate genes and 3:6
causal to non-causal ratio.
doi:10.1371/journal.pgen.1003224.g005
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the ANGPTL gene set (P~2:6E{05), which should be sufficient
to detect ANGPTL-phenotype association, using a gene set based
analysis in a whole-exome study, after multiple testing correction
(Table 2). The hybrid BOMP P-value was more significant than
either of its components (the BOMP burden and position
distribution scores). This result was consistent with the average
behavior of BOMP in our simulation-based analysis of power
(Figure 5). However, the two component scores did not yield an
improved hybrid score on every gene. For ANGPTL3, ANGPTL4,
and ANGPTL5, the hybrid score P-value was not as significant as
the P-values of the most significant component score. The burden-
based VT score (with bioinformatics score variant weighting) had
the most significant P-values for ANGPTL3 (P~0:015); the
BOMP position distribution score for ANGPTL4 (P~1:6E{05),
closely followed by VT (with bioinformatics scores) (P~1:7E
{05), and the overdispersion test SKAT (P~5:78E{05).
KBAC, with single directional scoring (only deleterious variants
counted) and threshold for rare variation set at MAFv1%, had
the most significant P-value for ANGPTL5 (P~0:023).
These results confirm previous reports that the performance of
current methods to detect causal variants depends on which genes
are selected for benchmarking [6,14].
Bipolar case-control study
We then used BOMP to test candidate gene sets in data from an
on-going whole exome sequencing study of bipolar disorder. We
examined whole-exome sequencing data on the first 191 cases and
107 controls from this study. These samples were sequenced in two
rounds, over a two-year period. In the first round, Nimblegen v1.0
arrays were used for exome capture and Illumina GAII platform
for next-generation sequencing. In the second round, Nimblegen
v2.0 arrays and the Illumina HiSeq2000 platform was used. Only
samples with target sequencing coverage of at least 80% at 206
sequencing depth were included for further analysis. Sequence
reads from the samples were aligned to the human reference
genome sequence database using BWA [24]. Variants were then
called after realignment around indels and recalibration of base
quality scores with GATK [25] in target regions. Quality control
measures for variant calling required coverage of at least 66depth
with a SNP quality score of 30 or higher to eliminate false-
positives. Variants were annotated to dbSNP135 and collected in
VCF files.
We obtained a collection of pathways for testing from
SynaptomeDB [26], a bioinformatics database that we developed
to collate available information on genes coding for proteins found
in synapses. In SynaptomeDB, a set-based analysis was performed
on gene sets from the MSigDB collection [27] to identify gene sets
that are enriched for synaptic genes. We extracted twenty gene sets
containing at least 100 genes that were most significantly enriched
for synaptic genes.
To control for differences in the number of exons targeted by
Nimblegen v1.0 and v2.0 (approximately 180,000 vs. 300,000
coding exons) in our analyses with BOMP, we only considered
variants in exons present in both Nimblegen kits. We used
OverlapSelect from the UCSC Kent source library to identify
variants in the shared exons. BOMP P-values and FDR were
computed for each of the twenty gene sets selected from
SynaptomeDB.
Seven of the gene sets were nominally associated with bipolar
disorder (Table 3). The most significant of these, the ‘‘MAPK
signaling pathway’’ defined by the KEGG Pathway Database,
trended toward significance after correcting for multiple gene sets
tested (nominal p-value = 0.0065;FDR=0.095). This gene set
consisted of 267 genes involved in the signaling pathway, including
68 found in neuronal synapses (Discussion).
To check for possible systematic bias in our Bipolar analysis e.g.,
effects of population substructure, we compared the observed
distribution of BOMP P-values with that expected under the null
hypothesis of no association. The resulting Q-Q plot (Figure S5) is
not heavily skewed or heavy-tailed. We also checked for possible
Figure 6. Example variation pattern in which position distribution outperforms burden tests. A toy example of a genomic region
containing variants (blue squares) in cases and controls. We assume that the region is important for phenotype. Variant counts in cases (red). Variant
counts in controls (purple). Cases and controls each have a total of 9 variants in this region, so Burden statistics (e.g., VT or BOMP burden) will not be
able to detect that the region is important for phenotype. BOMP’s position distribution statistic collapses variants into short, localized windows (red
dashed lines) and detects that the number of variants seen in cases and controls is different within the windows. We note that a method that does
not collapse variants, such as SKAT, does not have much power to detect the difference between cases and controls, because at each position the
number of variants in cases and controls is similar.
doi:10.1371/journal.pgen.1003224.g006
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bias resulting from the version changes in exome capture and
change from Illumina GAII to HiSeq2000 sequencing platforms
between rounds one and two. We performed PCA analysis with
EISENSTRAT [28], which revealed no significant differences in
the nature or frequency of variants identified in the two rounds
(Figure S6).
Computational time
In our simulations, analysis of an average-sized gene (500
codons), using 100,000 permutations, required wall-clock times of
32 s, 57.8 s, 1 m23 s, and 3 m4.2 s for case-control study sizes of
200, 1000, 2000, or 5000 (African American demographic model)
and 22.8 s, 1 m7.6 s, 1 m25.2 s, and 3 m9.6 s for European
American demographic model. For our gene set analyses with real
data from the bipolar case-control study (298 individuals), using
100,000 permutations to compute P-values, BOMP computation
time ranged from 10 m for a gene set with 101 genes to 4 h16 m
for a gene set with 648 genes (Table 3). All computations were
done on a machine with four dual-core 2.6 GHz AMD Processors
and 16 Gb memory.
Discussion
In this work, we introduce and explore the power of a new
hybrid likelihood model BOMP to detect causal variants
Figure 7. Analytical comparison of SKAT, BOMP, and VT on a toy example. Genotypes of 8 cases and 8 controls at 10 positions. Matrix
column colors: controls = light blue, cases = light red. Position distribution bar colors: controls = blue, cases = red. Detailed description is in the section
‘‘Toy example with analytical calculations’’ (Text S1).
doi:10.1371/journal.pgen.1003224.g007
Table 2. Dallas Heart Study.
Method ANGPTL ANGPTL3 ANGPTL4 ANGPTL5
Hybrid BOMP+VEST 2.6E-05 0.09 2.3E-05 0.15
Hybrid BOMP 3.7E-05 0.14 4.3E-05 0.14
VT+VEST 8.3E-05 0.015 1.7E-05 0.18
SKAT 1.06E-04 0.068 5.78E-05 0.29
Positional BOMP 1.5E-04 0.4 1.6E-05 0.3
KBAC (1D,5P) 2.9E-04 0.031 1.5E-04 0.17
KBAC (2D,5P) 5.5E-04 0.064 3.2E-04 0.31
KBAC (1D,1P) 2.9E-03 0.24 0.033 0.023
VT 3.8E-03 0.04 4.56E-03 0.1
KBAC (2D,1P) 5.8E-03 0.47 0.067 0.045
Burden BOMP+VEST 0.006 0.04 0.008 0.09
P-values of association between dichotomized triglyceride levels and variation
in three ANGPTL family genes sequenced in Dallas Heart Study. ANGPTL -
multiple gene set including ANGPTL3, ANGPTL4, and ANGPTL5. The most
significant P-value for each is highlighted in bold. BOMP= combined Burden
and Position statistics VT = variable threshold burden test [10] SKAT = sequence
kernel association test (linear weighting version) [12], KBAC= Kernel-based
adaptive cluster [20] (1D= single direction, 2D= two direction, 1P = rare variants
defined as v1% MAF, 5P = rare variants defined as v5% MAF). VEST = BOMP
and VT with VEST score variant weighting.
doi:10.1371/journal.pgen.1003224.t002
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underlying dichotomous disease phenotypes. We compared its
power with that of several leading methods designed to detect
causal variation in whole-exome case-control studies. We per-
formed simulated case-control studies, using a variety of sizes,
demographic models, and disease etiologies. The hybrid BOMP
model had good power compared to several popular methods
(Figure 1, Figure 2, Figure 3). Its strengths were most apparent
when we tested gene sets for association with phenotype, when
protective or common variants were present, and when a
phenotype was associated with variants that cluster in key regions
on a gene.
Because no current variant collapsing methods have been
shown to be best for every disease etiology [6], we were
particularly interested in how the performance of BOMP and
other methods varied by etiology. Our case-control study
simulations were designed to represent eight etiologies (Table 1).
Etiologies were defined by properties of their causal variants,
based on range of minor allele frequencies, selection coefficients,
position distribution, and mean effect sizes. Some etiologies
include protective variants, while others include only deleterious
variants. For all of our etiologies, only coding, non-silent variants
were considered to have an impact. Importantly, our etiologies are
defined in a probabilistic way since we allow for a randomly
selected fraction of variants which meet the causality criteria for an
etiology to have no effect (Methods). As a result, in the rare variant
etiology, all causal variants are rare, but not all rare variants are
causal, etc.. Method performance also varied by the population
demographic models (European-American exponential growth
and African-American simple bottleneck) used in our simulations.
We provide details of how the performance of all tested methods
was affected by disease etiology and demographic model in Text
S1.
Gene set simulations
We considered the possibility that differences between cases and
controls might be detected with respect to a gene set, rather than a
single gene [29]. We tested the methods, using gene sets of
different sizes (Figure 2), different combinations of disease
etiologies (Figure 3, Figure S3), and different fractions of genes
containing causal variants (Figure 2). Of the tested methods,
burden statistics and KBAC were the least effective at detecting
gene sets containing causal variants. SKAT and the BOMP
position distribution statistic were the most effective.
Biologically, we don’t expect that every gene in a real gene set
will contain causal variants. Thus our simulated gene sets were
designed to contain a mix of genes with causal variants and those
without. The burden tests (VT and BOMP burden) were not able
to effectively capture the difference between the two and lost
power as the number of non-causal variants in the simulations
increased (Figure 2). The genotype vectors computed by KBAC
become larger and more heterogeneous when applied to a gene
set, rather than a single gene. Thus, the KBAC strategy of
leveraging the number of shared genotype vectors among cases
and/or controls is less effective when applied to gene sets than to
single genes. The BOMP hybrid likelihood statistic (with strong
contributions from the BOMP position distribution statistic), and
SKAT were the most powerful when applied to gene sets, rather
than single genes. We attribute this result to the increase in the
number of significant localized units in a gene set that contains
more than one causal gene.
We found in our simulations that a case-control study size of
1000 individuals (500 cases, 500 controls) BOMP was sufficiently
powered to detect causal variants in situations when a good
candidate gene set (of approximately 25 genes) was known.
However, if the ratio of causal to non-causal genes in the selected
gene set was low (1:3) and/or the individuals in the study carried a
high proportion of rare (MAFv1%) or singleton variants, the
power of the BOMP hybrid model, like all the methods examined,
was diminished. This result highlights the importance of very high
quality gene sets derived either from disease experts or improved
bioinformatics tools for success in real data analysis.
Dallas Heart Study benchmark set
When we applied BOMP, VT, SKAT, and KBAC to an
empirical dataset, each method displayed both strengths and
weaknesses. While the dataset is small, it is interesting to note that
P-values of association between variant ANGPTL family genes
and dichotomized serum triglyceride levels from the Dallas Heart
Study were most signicant for the BOMP hybrid model, when the
genes were considered together as a gene set. However, the burden
statistic VT had the most signicant P-value for ANGPTL3, and the
KBAC P-value was the most significant for ANGPTL5 (specically
with single directional scoring and threshold for rare variation set
at MAF v1%). For ANGPTL4, the most signicant P-values were
from the BOMP position distribution score, VT, and SKAT. Each
of these genes had a different pattern of variation frequencies in
cases and controls, which presented advantages and obstacles for
each method. For example, ANGPTL3 had a high frequency
variant (M259T) that occurred more often in cases than controls
and many ‘‘noisy’’ rare/singleton variants that occurred either in
cases or controls. VT took advantage of the signal in M259T
because its threshold adapted to maximize the burden increase in
cases versus controls, and thus M259T was included in its burden
calculation. BOMPs burden statistic did not give as much
importance to M259T, because it downweights high frequency
variants. KBAC included M259T only when its allele frequency
threshold parameter was set to 5% but was penalized when it was
set to 1%.
BOMP is not designed to be adjusted for additional covariates,
which are often available in disease studies. For example, it is not
designed to explicitly deal with different ancestries in a structured
population. However, if the true population structure is known
and the number of subpopulations is not too large, we can run
analyses with stratification to get around this problem, as we (and
the authors of the VT and SKAT papers) did for ANGPTL family
genes in the Dallas Heart Study [10,12]. Using this strategy, one
begins with a quantitative trait (serum triglyceride levels), stratifies
individuals into groups, then identifies extreme phenotype
individuals from each group. Cases are then those individuals
from all groups at one extreme and controls are those individuals
from all groups at the other extreme. An alternative strategy is to
permute case-control labels only within each group to generate a
correct null distribution.
Incorporating bioinformatics scoring of variants (by VEST)
yielded improved P-values for both BOMP and VT on the Dallas
Heart Study data. While it has been suggested that bioinformatics
misclassification of variants might be more of a liability than a
benefit, our results (albeit on a small gene set) suggest the opposite.
Functional classification of variants in both coding and non-coding
regions of the genome is an active research area in bioinformatics,
and as methods improve, it is likely that they will increasingly
contribute to statistical analysis of causal variation.
Bipolar whole-exome sequencing, case-control study
Finally, we applied BOMP (with VEST scoring) to test
candidate gene sets in data from an on-going whole-exome study
of bipolar disorder. The top gene set was the ‘‘MAPK signaling
pathway’’ defined from the KEGG Pathway Database
Hybrid Likelihood Model for Disease Association
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(map04010). This is a highly conserved pathway that is centrally
involved in cell proliferation, differentiation and migration. In the
nervous system, it is at the nexus of multiple neuronal signaling
cascades thought to mediate certain forms of synaptic plasticity
[30]. Interestingly, the pathway has been implicated before in the
etiopathogenesis of bipolar disorder [18] and a number of studies
have shown that two most commonly used anti-manic agents,
lithium and valproate, activate the MAPK signaling cascade,
which may in part be responsible for their therapeutic effects [31].
One of the key genes in this pathway, DUSP6, a cytoplasmic
phosphatase that plays an active role in MAPK signaling by
regulating the intensity and duration of MAPK activity and by
helping to shuttle MAPK between the cytoplasm and nucleus, has
been associated with bipolar disorder [32,33]. There are several
other genes of considerable interest in this gene set, as they have
been implicated previously in the genetics of bipolar disorder. For
example, this pathway also contains CACNA1C and other
members of the family of voltage gated calcium ion channels.
CACNA1C was recently implicated as one of the most significant
genes in a mega-analysis of genome-wide association studies
(GWAS) of bipolar disorder carried out by the Psychiatric GWAS
Consortium (PGC) [34]. This gene set also contains the
phospholipase A2 family of genes. Phospholipases mediate the
release of arachidonic acid from membrane phospholipids.
Arachidonic acids are involved in brain signaling processes that
mediate a number of effects, and there is growing evidence that
the arachidonic acid signaling cascade may be a common target of
multiple diverse mood stabilizers [35].
Complex diseases are expected to have considerable genetic
heterogeneity i.e., they may be the consequence of alterations in
hundreds of potentially causal genes, and affected individuals
may have causal and/or protective variants in different subsets of
these genes. The simulations done in this work reflect this
heterogeneity (example in Figure S7), and we still retain good
power.
Bayesian extensions of our work could include prior knowledge
about the probability that a functional group of interest is
associated with the phenotype. For example, if the functional
group is a gene, prior evidence could come from expert knowledge
based on previous functional and/or case-control studies. By
combining the log likelihood ratio (Equation 1) with a log prior
ratio, we could estimate the log ratio of the full posterior
distributions.
In summary, we have developed a new method for identifying
causal variants in high-throughput sequencing data from case-
control studies. It is shown to have good power relative to other
leading methods and can be flexibly used in a variety of realistic
scenarios. The genetic architecture of most common human
diseases is likely complex, involving variants with a wide spectrum
of frequencies from rare to common and contributing to disease
through a number of inter-related pathways. The emergence of
whole-exome and genome sequencing studies promises to accel-
erate our ability to interrogate the genetic architecture of these
disease. However, a major challenge remains how to make sense of
the enormous amounts of data generated by such studies. Our new
method provides another useful tool in a growing toolbox for
analyzing the data from such studies.
Methods
BOMP (Burden Or Mutation Position statistics), the hybrid
likelihood model proposed here, consists of two likelihood ratio
tests (mutation burden and mutation position distribution statistics)
with the same general form,
Lj~log
L(FGj DHA)
L(FGj DH0)
 
ð1Þ
and tests the evidence for the alternative hypothesis HA that a
functional group (FG) of interest is associated with a disease
phenotype, compared to the null hypothesis H0 that they are not
associated. Higher values of Lj indicate stronger association
between unit j and the disease phenotype. In this work, the
functional groups of interest are either single genes or sets of
multiple genes.
BOMP mutation burden statistic
The first likelihood ratio test is based on comparing mutation
burden in cases and controls. Each individual is represented with a
Bernoulli random variable, which is 1 if the individual’s burden
exceeds a burden threshold, and 0 otherwise. To model the
likelihood, we assume that individual burden status is independent
and identically distributed (IID). The ratio compares an alternative
hypothesis that the probability of exceeding the burden threshold
is higher in cases than in controls and the null hypothesis (that
probabilities are equal or lower in cases than in controls).
Biologically, the IID assumption is not necessarily true. We
control for such violations by assessing the statistical significance of
the likelihood ratio by permuting case and control labels (Figure
S8).
Individual burden. For individual k the gene burden of gj is
Sgj,k~
Xnj,k
i~1
xi,k, ð2Þ
where nj,k is the number of variants carried by individual k in gene
j and xi,k is the genotype of variant vi.
Individual burden thresholds. A binary variable is used to
label individuals whose mutation burden in a gene of interest
exceeds a critical threshold. If the burden of gene gj in individual k
is greater than or equal to the threshold t, then it is considered to
be disease phenotype associated for that individual and Ygj,k~1 (0
otherwise). Because genes are heterogeneous in size, functional
importance, mutation rate, and tolerance to variation, each gene
may have a different value of t. For each gene j, this cutoff tj is
computed by iterating over all cut-offs and selecting the one that
maximizes its mutation burden statistic (Equation 4).
Aggregated burdens. The Ygj,k values are then aggregated
by summing over cases and controls:
TAj ~
X
k[cases
Ygj,k
TUj ~
X
k[controls
Ygj,k
The maximum likelihood estimate of the probability that the
mutation burden of gene j exceeds the threshold in cases is then
p^Aj ~
1
mz2
TAj z1
 
, the estimate for controls is
p^Uj ~
1
lz2
TUj z1
 
and the estimate for both cases and controls
is p^j~
1
mzlz4
TAj zT
U
j z2
 
, where m is the number of cases
and l the number of controls. The probability estimates p^Aj , p^
U
j ,
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and p^j are used as the parameters of three Bernoulli distributions
(one for cases, one for controls, and one for cases and controls
together). Pseudocounts are added to avoid zero counts. The
aggregated burden calculation (without pseudocounts) is illustrated
in Figure 8 (and Figure 7).
Burden likelihood ratio statistic. For a gene gj the
mutation burden statistic is defined as a ratio of Bernoulli
likelihoods:
LB(gj)~log
LB
A|LB
U
LB
AzU
 
ð3Þ
~log
p^Aj
 TA
j
1{p^Aj
  m{TA
j
 
p^Uj
 TU
j
1{p^Uj
  l{TU
j
 
p^j
  TA
j
zTU
j
 
1{p^j
  mzl{TA
j
{TU
j
 
0
BBB@
1
CCCAð4Þ
where m is the number of cases, l the number of controls; TAj is the
number of cases whose mutation burden in gj exceeds an
optimized threshold (Individual Burden Thresholds); TUj is the
number of controls exceeding the threshold; p^Aj is the maximum
likelihood estimate of the probability that the burden of gene j
exceeds the threshold in cases, p^Uj is the estimate that gene j
exceeds the threshold in controls, p^j is the estimate that gene j
exceeds the threshold in both cases and controls. First, we consider
only genes with higher burden in the cases, for which p^Aj §p^Uj .
Next, for the remaining genes, we modify Equation 4,
~log
p^Uj
 TA
j
1{p^Uj
  m{TA
j
 
p^Aj
 TU
j
1{p^Aj
  l{TU
j
 
p^j
  TA
j
zTU
j
 
1{p^j
  mzl{TA
j
{TU
j
 
0
BBB@
1
CCCAð5Þ
Thus genes with higher burdens in cases than controls get a high
value and those with higher burdens in controls than cases get a
low value.
It follows that under HA, the number of cases in which the
burden of gene j exceeds the threshold will be larger than in
controls, and that under H0, they will not be different.
If a gene set rather than a single gene is used as the functional
group, the burden is aggregated across all genes in the set, and the
procedure is otherwise identical.
BOMP mutation position distribution statistic
The second likelihood ratio test is based on comparing the
position distribution of mutations in cases and controls. The
codons of a gene are partitioned into windows and mutation
count (burden score) is computed for each window in cases only,
controls only, and in cases and controls together. To model the
likelihood, each window mutation count is considered to be a
random variable in a multinomial distribution. If the partition
contains d windows, there are d possible outcomes for each
mutation. There are also d multinomial parameters for the
partition.
Window mutation counts. Let the window mutation counts
in the multinomial distributions be WAx,j , W
U
x,j , and W
AzU
x,j (cases
only, controls only, and in cases and controls together)
for cases WAx,j~
X
k[cases
Sx,j,k, for controls W
U
x,j~
X
k[controls
Sx,j,k,
for cases and controls WAzUx,j ~
X
k[cases and controls
Sx,j,k:
where Sx,j,k (computed as in Equation 2) is the score for individual
k in window x.
The maximum likelihood estimate of the multinomial param-
eters (including pseudocounts) is then
p^Ax,j~
WAx,jz1P
x W
A
x,jz1
  ð6Þ
p^Ux,j~
WUx,jz1P
x W
U
x,jz1
  ð7Þ
p^AzUx,j ~
WAzUx,j z2P
x W
AzU
x,j z2
  ð8Þ
Position distribution likelihood ratio statistic. For a gene
gj , the statistic is defined as a ratio of multinomial likelihoods:
LP(gj)~log
LP
A|LP
U
LP
AzU
 
ð9Þ
where
for cases LP
A~P
x
p^Ax,j
 WA
x,j
z1
ð10Þ
for controls LP
U~P
x
p^Ux,j
 WU
x,j
z1
ð11Þ
for cases and controls LP
AzU~P
x
p^x,j
 WAzU
x,j
z2
: ð12Þ
It follows that underHA, the likelihood for cases will be different
than for controls, and that under H0, they are not different. In
contrast to the mutation burden statistic, there is no directionality
in the mutation position distribution statistic, because LP(gj) will
be large when either p^Ax,j or p^
U
x,j is large.
A toy example of aggregated window mutation count calcula-
tion is illustrated in Figure 8 (and Figure 7).
Windows and sequence segmentations. Each gene has
many possible window partitions, and we don’t know in advance
which is the most informative for the position distribution statistic.
One way to create candidate window partitions (i.e., sequence
segmentations) for a gene of length L is to select a window size s
and a series of possible offsets, based on a selected shift increment
t. Each offset generates a new segmentation (Figure S9). For
Hybrid Likelihood Model for Disease Association
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Figure 8. Components of BOMP Hybrid Likelihood Model compared. A. Mutation burden statistic. The Mutation burden statistic uses the
aggregated burden for cases, TAj , and controls T
U
j . B. Mutation position distribution statistic. Aggregated window mutation counts are calculated for
cases, WAj , controls, W
U
j , and cases and controls combined, W
AzU
j , across x windows.
doi:10.1371/journal.pgen.1003224.g008
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example, if the window size is 8 and the shift increment is 1, the
first offset begins at the first position of the gene and generates a
segmentation of q
L
8
r windows. The second offset will begin at
position 2 of the gene and generate a new segmentation of
q
L{1
8
rz1 windows, etc. In this work we used four combinations
of window size s and shift increment t: (8,1), (16,2), (32,4) and
(64,8), yielding 32 candidate segmentations for a gene. These
choices were not optimized and can be adjusted, according to user
preference and/or prior knowledge. The best segmentation is
selected by computing the likelihood ratio LP(gj) (Equation 9) for
each segmentation and picking the segmentation with the largest
LP(gj). Alternatively, this likelihood ratio can be modified by
computing WAx,j , W
U
x,j , and W
AzU
x,j with respect to total positions
mutated, rather than total number of mutations.
For the position distribution statistic, if a gene set rather than a
single gene is used as a functional group, the best window
segmentation is computed for each gene, and the calculation of the
position distribution statistic is otherwise identical.
The mutation burden and mutation position burden statistics
are combined into a single log likelihood ratio,
Lgj~LB(gj)zLP(gj): ð13Þ
Controlling false positives through permutation
P-values for each Lgj are computed with a null distribution,
generated by repeated permutation of case and control labels.
All parameters of LB(gj) and LP(gj), including the maximum
likelihood burden threshold and segmentation pattern, are
calculated initially for empirical data and then re-calculated
for each iteration of the permutation. Thus, N iterations yields
N null L(n)gj where n ranges from 1 to N (Figure S8, Figure S10).
The permutation controls for confounding effects, such as
properties that characterize a particular gene or region of
interest (i.e., nucleotide diversity, GC content, and recombi-
nation rate), which are the same when used to estimate Lgj and
each null L(n)gj .
After N iterations (e.g., N~106 )
Pgj~
# null L(n)gj §Lgj
 
z1
Nz1
ð14Þ
While LB(gj) and LP(gj) are not independent, using the
permutation test yields an accurate P-value estimate, because
any dependencies in Lgj are reproduced in each nullL
(n)
gj
.
Extensions to the basic method
Genetic models. Either dominant or additive genetic models
can be specified. Under the dominant genetic model, both
homozygous and heterozygous variants have xi~1; under the
additive model, homozygous variants have xi~2 and heterozy-
gous variants xi~1. For all experiments in this work, additive
models were used.
Variant scores. The Individual Burden can be modified by
incorporation of score coefficients so that Sgj,k~
Xnj,k
i~1
xi,ksi. The
score for a variant vi can be either a bioinformatics-based score
si~fi, an allele-frequency-based score si~
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
hi(1{hi)
p , following
[9,10]; or the product of both si~fi
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
hi(1{hi)
p . Next we explain
how these scores are calculated. In this work, variant scores were
used only in the burden statistic. The allele-frequency-based score
was used for all simulations and the product of allele-frequency
and bioinformatics scores was used on all empirical data.
Bioinformatics scores. Each nonsilent variant vi can be
assigned a score fi[½0,1 to represent its contribution to a disease
phenotype of interest, where fi~0 indicates no contribution and
fi~1 indicates a strong contribution. These scores are estimated
with Variant Effect Scoring Tool (VEST). Variants causing nonsense,
nonstop or frameshift alterations to a gene’s protein product
receive fi~1. Variants causing missense alterations are scored
with a Random Forest classifier [36,37]; the score is the fraction of
decision trees in the forest that classified the variant as deleterious.
Alternatively, other bioinformatics methods that score missense
variants can be used to generate fi values, if scaled to range from 0
to 1.
The Variant Effect Scoring Tool is a Random Forest classifier,
trained with the CHASM software suite’s Classifier Pack and
SNVBox [38]. The Forest contains 1000 decision trees. The
positive class of 45,000+ missense variants is taken from the
Human Gene Mutation Database (HGMD) [39]. The negative
class of 45,000+ missense variants is randomly selected from
variants validated by the 1000genomes project [40] in the SNP135
table of the UCSC Genome Browser database [41]. Each missense
variant is represented by 86 features in SNVBox, including
conservation scores, amino acid residue substitution scores,
UniProtKB annotations [42], and predicted local protein struc-
ture.
Allele-frequency-based scores. For each vi, we estimate its
mean population allele frequency hi as follows:
E½hi~x
A
i zx
U
i z1
2Nz2
ð15Þ
where xAi and x
U
i are allele counts of variant vi in cases and
controls, respectively; N is the number of individuals in both cases
and controls; and the constants are pseudocounts from a beta
prior.
Simulation framework
Simulated case-control studies are generated using two demo-
graphic growth models, eight disease etiologies, and a stochastic
model of genotype-phenotype association.
Generating genomic populations. The general Wright-
Fisher model/forward population genetic simulation tool
SFS_code [43] is used to generate 100 effective genomic
populations and to sample 1,000,000 haplotypes per population.
As in [13], the simulated haplotypes in each population are
randomly paired to generate 500,000 diploid individuals. Two
demographic growth structures are used: an exponential growth
model fitted to deep resequencing data from European Americans
[19] and a simple bottleneck model fitted to whole-genome
polymorphism data from African-Americans [44]. For the
exponential growth demographic model, distribution of fitness effects
of new mutations (DFE) is modeled with a two-component gamma
mixture (similar to [19]). For the simple bottleneck model, DFE
was modeled as described in [44] (Text S1:Demographic Models).
Following [19], the mutation rate is set to 1:8|10{8 per
generation for all simulations.
Generating phenotypic traits for individuals with a single
causal gene. The individuals in a population are then
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associated with a quantitative phenotypic trait, which we assume
drives a disease, so that individuals with high values of the trait will
have the disease and those with low values of the trait will not.
Eight possible disease etiologies are considered (Table 1). Each
etiology is defined by properties of its causal variants. Variants can
be rare, low frequency, or common. They can occur only in key
functional regions. They can have small or large effects (value of k
in Equation 17). Protective modifier variants may or may not be
present. In this work, only coding, non-synonymous variants are
considered as causal or protective for all etiologies. (However,
disease etiologies that consider silent variants, which impact gene
regulation, could also be defined.) For etiologies with key region
variants, we used haplotypes that contained multiple coding
segments (100 segments, each 30 bases long). Otherwise haplo-
types contained a single coding segment of 1500 bases.
To generate the phenotypic traits for the genomic populations,
we select a disease etiology and a population that contains variants
meeting the criteria for causality in that etiology (Table 1).
Next the quantitative disease trait QT is generated for each
individual in the population, using an approach based on [19].
Trait values are drawn from Gaussian distributions, such that
individuals with no causal variants have
QT*N(m,s),(m,s)~(0,1): ð16Þ
Individuals with n causal variants have
QT*N(mznks,s),(m,s)~(0,1): ð17Þ
where ks is the mean shift in trait value (the shift per variant) for
an individual.
To match the expected effect size of significant common and
rare variants in GWAS, effect sizes of 0:1s for common
variants (Text S1: Effect size of common variants) and
0:5s{1:0s for rare variants are used. The strongest effects
are 1:0s for rare variants in Key Regions. We assume that
these variants occur at functionally important positions and
that in a gene of interest, they are unlikely to occur more than
once in a single individual. Our choice of effect size is
somewhat larger than that used by Kryukov et al. [19], who use
0:25s{0:5s for rare variants. To account for heterogeneity
within a particular disease etiology, effect size can be 0 for a
designated fraction of causal variants.
Case-control study generation. At this stage, each popula-
tion consists of genomic individuals, each with a real-valued
quantitative trait. To construct the case-control studies, an
extreme phenotype model is used. Disease prevalence is set at
1%, i.e., the 1% of individuals in the selected population with the
highest values of QT are considered affected and the 25% of
individuals with the lowest values of QT unaffected.
Case-control studies are generated by sampling without
replacement from affected and unaffected groups in a population.
Individuals with intermediate phenotype values are not included in
case-control studies. The random process used to generate QT
(Generating phenotypic traits for individuals with a single causal
gene) ensures varied penetrance and phenocopy rates in each case-
control study, e.g., some individuals carrying deleterious variants
are not affected, while some with no deleterious variants are
affected.
Null case-control study. A null case-control sample is also
generated, with no disease etiology, in which the phenotypic trait
is drawn from a standard normal distribution for every individual
in the sample.
Generalization to multiple genes. For a scenario in which
the functional group of interest is a gene set e.g., involved in a
pathway or biological process, we construct a new population of
500,000 individuals, in which each individual has multiple genes.
This population is created by sampling genes from the diploid
gene populations generated previously (Generating genomic
populations). Next, we specify a gene set size and fraction of
genes in the gene set that contain causal variants. A disease
etiology is then randomly selected for each gene that contains
causal variants. Finally, the phenotypic trait for each individual in
the population is generated using Equations 16 and 17. Gene set
case-control studies were generated with the same protocol as for
single causal genes.
Supporting Information
Figure S1 Power estimates for BOMP, VT, SKAT, KBAC for
case-control study with 10,000 individuals. (KBAC1P=minor
allele frequency defined as v1%, KBAC5P=minor allele
frequency defined as v5%). Each column represents power
estimates for each method, based on 250 simulated case-control
studies. All case-control studies had 10,000 genomic individuals,
each with a single gene. AA= the case-control studies were drawn
from gene populations generated with an African-American
simple bottleneck demographic model. EA= the case-control
studies were drawn from gene populations generated with a
European-American exponential growth demographic model. The
eight variant causality (disease etiology) models are defined in
Table 1. Since the European-American demographic model does
not account for common or protective variants, etiologies
involving common or protective variants were only considered
for the African-American demographic model.
(PDF)
Figure S2 Distributions of allele frequencies and raw allele
counts in simulated European-American and African-American
populations. The European-American population consists almost
entirely of rare variants, while the African-American population
contains a wider range of rare, low-frequency, and common
variants. Percentage of variants with allele frequencies and raw
allele counts in the designated ranges are shown. Because w99%
of European-American allele frequencies arev0:1%, we include a
blow-up of frequenciesw0:1%, which range from 0.05% to 0.2%.
Demographic models shown in Figure S11.
(PDF)
Figure S3 Nine multinomial distributions used to construct sets
of multiple candidate genes for case-control studies. Each
multinomial distribution is named for its dominant disease
etiology.
(PDF)
Figure S4 Power of position distribution statistics compared to
burden methods and SKAT. Burden tests outperform the position
distribution statistic when causal variants are rare and are not clustered,
as in our simulations of Rare Variant disease etiology and European-
American demographic. The position distribution test outperforms
burden tests when the number of rare variants is similar in cases and
controls, but where cases and controls differ with respect to the position
distribution of the variants, as in simulations of Key Region Variant
disease etiology and European-American demographic. Both collaps-
ing burden and position distribution tests outperform SKAT when
causal variants are very rare. RareEA=rare variant disease etiology
(Table 1) and European-American demographic model. KeyRegio-
nEA=key region variant disease etiology (Table 1) and European-
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American demographic model. Power shown on Y-axis. Simulations
with 10,000 samples are shown.
(PDF)
Figure S5 Q-Q plot of BOMP P-values for all genes in the
Bipolar case-control study. The plot shows no evidence of heavy
skew or heavy tails, indicating that there is no systematic bias in
our analysis. Empirical P-values are below the line because the
BOMP statistic is not continuous for genes with few variants in
only a few samples, leading to conservative P-values.
(PNG)
Figure S6 PCA plot showing the overlap of bipolar samples and
controls sequenced during rounds 1 and 2. Plot obtained using
EIGENSTRAT [28], where the first and second components of
the model (PC1 and PC2, respectively) are shown. The analysis
does not show significant differences in the nature or frequency of
variants identified in the two rounds. Round 1=Nimblegen v1.0
and Illumina GAII, Round 2=Nimblegen v2.0 and Illumina
HiSeq2000.
(PNG)
Figure S7 Example of how our simulations capture genetic
heterogeneity in complex disease. Each horizontal grid line
represents a genomic individual. (Cases and controls shown
separately.) Each vertical gridline represents a gene. Causal
variants (both deleterious and protective) are shown as triangles.
Different case individuals have different patterns of causal variants
and the allele frequencies of the variants range from rare (1 allele)
to common (190 alleles). Causal variants are also observed in the
control individuals. Type =Downward pointing triangles are
deleterious variants, upward pointing triangles are protective
variants. (200 genomic individuals from African-American demo-
graphic model are shown).
(PDF)
Figure S8 Flow chart for calculation of mutation burden
statistic. The statistic is first calculated from empirical data (by
following the blue and black arrows). The null mutation burden
statistics are calculated by following the red and black arrows. Key
steps in the calculation are: computing the burden for each
individual; sorting the individual burdens into a ranked list, where
m denotes list rank; selecting a candidate burden threshold;
computing maximum likelihood estimates of Bernoulli parameters
at this threshold; computing the LLR (log-likelihood ratio) with
these parameters. Candidate burden thresholds are iteratively
tested and the threshold yielding the largest LLR is returned. To
generate the null distribution, case-control labels are repeatedly
permuted and the key steps are followed to compute one point in
the null. The permuted null distribution is estimated by repeating
steps 1–4 10,000 times (or user-adjusted value) and used to
compute the p-value for the statistic.
(PDF)
Figure S9 Window and sequence segmentations. The mutation
position distribution statistic requires a segmentation for a
sequence of interest (e.g., a gene). We generate candidate
segmentations by selecting a window size s and allowing a series
of possible offsets, based on a selected shift increment t. In this
example, we illustrate the eight possible window segmentations of
a gene with 24 codons (represented by rectangles), using a window
size of 8 and a shift increment of 1.
(PDF)
Figure S10 Flow chart for calculation of position distribution
statistic. The statistic is first calculated from empirical data (by
following the blue and black arrows). The null position distribution
statistics are calculated by following the red and black arrows. Key
steps in the calculation are: choice of (user-selected) window sizes s
and shift increment t to generate a set of gene segmentations (Each
unique segmentation is defined by s, t, and shift, which represents
the current segmentation offset); estimation of d parameters for
each of three multinomial distributions – cases, controls, and cases
and controls together – (for a segmentation with d windows);
computation of log likelihood ratio; finding the largest log
likelihood ratio for all segmentations. To generate the null
distribution, case-control labels are repeatedly permuted and the
key steps are followed to compute one point in the null. The
permuted null distribution is estimated by repeating steps 1–4
10,000 times (or user-adjusted value) and used to compute the p-
value for the statistic.
(PDF)
Figure S11 Demographic models of European-American and
African-American populations. The models were fit to European-
American [19] and African-American sequencing data [44]
(PDF)
Table S1 BOMP, VT, and SKAT comparison. Approaches to
variant collapsing, variant importance, and choice of statistical
framework define differences and similarities among BOMP, VT,
and SKAT. A. Variant collapsing strategies. VT and BOMP
burden both collapse variants across a genomic region. SKAT
does not do collapsing and considers variants one at a time.
BOMP position distribution collapses variants across local
windows over a genomic region. These different collapsing
strategies are illustrated in a toy example in Figure 8 of our main
manuscript. B. Variant importance. All methods assume that some
variants are more important than others. This idea is implemented
by either filtering and/or weighting variants. C. Statistical
framework. VT and BOMP burden both use a summary statistic
to compare burden in cases and controls and assess the statistical
significance of the statistic with permutation. For VT, individual
burdens are summed over the case group and over the control
group and summarized by the difference in Z-score between the
two groups. For BOMP burden, individual burden is dichoto-
mized for each sample, by selecting a burden threshold. The
probability of exceeding the burden threshold for cases and for
controls is estimated. The difference between the two is compared
with a log-likelihood ratio. For SKAT, phenotypic labels (case or
control) are directly regressed for each variant. The coefficient for
each variant is tested by comparing it to 0, with a variance-
component score test. Statistical significance is calculated analyt-
ically. For BOMP position distribution, the difference of
distributions of variants over local windows between cases and
controls is modeled by multinomial likelihood and then summa-
rized by a log-likelihood ratio.
(PDF)
Text S1 Supplementary Material.
(PDF)
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